BG00012 Phase 3 109-MS-301 and 109-MS-302 Thursday, 07 September 2006

DISTRIBUTION / ATTENDEES





MINUTES


Study Status

- 1. Protocol changes (as per email)
 - Annual Relapse Rate at 2 years will be the primary endpoint. Proportion relapsing will move to a secondary endpoint.
 - Addition of 480 mg dose arm. Increase in number of patients is off-set by decrease in changing the endpoint. N stays about the same.
 - 301 becomes a 1:1:1, 302 becomes a 1:1:1:1
 - Avonex will be offered as rescue therapy (after 48 wks) once a patient has had two relapses ("banking" of a relapse will be removed, now relapses will count from the moment a patient enters the trial).

BG12 SMT Meeting Minutes

07 September 06





CRO Kick-Off Meeting/Investigator Meeting Update


Kick off is tentatively planned for October 3rd and 4th in the UK office. Date will depend on when
protocol is signed off.

Action: to update team on details

 Investigator meeting planned for end of January / early February, depending on protocol sign off.

Action: To follow up with meeting planner for ideas on venues close to a large international airport.







ACTION ITEMS

IB & ICF				ICF to be modified due to results from EOP2
Review of international model ICF		07 Sept 06	29 Sept 06	meeting
Review of NA model ICF	RL	07 Sept 06		
Review of all supplemental ICFs (MRI, Relapse, PHI, Genetics)		07 Sept 06	Pending	
Coordination of final regs sign off ICFs	RL.	07 Sept 06	29 Sept 06	
Condensed team (stats, medical, project management) to review ICF for 301	Stats, Medical and Project	07 Sept 06		
CRO Kick Off Meeting	5.3			CRO kick off moved from mid-Sept to first week Oct
to distribute agenda and attendee details to the team when details have been confirmed.		07 Sept 06	Pending	
to follow up with meeting planner for ideas on venues close to a large international airport.		07 Sept 06		



